UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Management and prognosis of bullous pemphigoid

Authors
Dedee F Murrell, MD
Mae Ramirez-Quizon, MD
Section Editor
John J Zone, MD
Deputy Editor
Abena O Ofori, MD

INTRODUCTION

Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by autoantibody deposition at the epithelial basement membrane zone. The disorder most frequently affects elderly adults and classically presents with generalized pruritic urticarial plaques and tense subepithelial blisters (picture 1A-C).

First-line therapy for bullous pemphigoid consists of topical or systemic corticosteroids; both interventions are rapidly effective for this disease. Additional immunomodulatory therapies are often added to treatment to minimize the adverse effects of chronic corticosteroid therapy or to augment improvement in the disease.

The management of bullous pemphigoid will be reviewed here. The epidemiology, pathogenesis, clinical features, and diagnosis of bullous pemphigoid are discussed separately. (See "Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid" and "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid".)

APPROACH TO THERAPY

Goals of treatment — The major goals for the treatment of bullous pemphigoid (BP) are as follows:

Decrease blister formation and pruritus

                              

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Sep 18 00:00:00 GMT 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Daniel BS, Borradori L, Hall RP 3rd, Murrell DF. Evidence-based management of bullous pemphigoid. Dermatol Clin 2011; 29:613.
  2. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346:321.
  3. Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009; 129:1681.
  4. Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012; 66:479.
  5. Campbell LS, Chevalier M, Levy RA, Rhodes A. Hypothalamic-pituitary-adrenal axis suppression related to topical glucocorticoid therapy in a child with psoriatic exfoliative erythroderma. Pediatr Dermatol 2012; 29:101.
  6. Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29:501.
  7. Keipert JA, Kelly R. Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate. Med J Aust 1971; 1:542.
  8. Dreno B, Sassolas B, Lacour P, et al. [Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study]. Ann Dermatol Venereol 1993; 120:518.
  9. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010; :CD002292.
  10. Morel P, Guillaume JC. [Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study]. Ann Dermatol Venereol 1984; 111:925.
  11. Frew JW, Murrell DF. Corticosteroid use in autoimmune blistering diseases. Immunol Allergy Clin North Am 2012; 32:283.
  12. Stanley JR. Bullous Pemphigoid. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K (Ed), McGraw-Hill, 2008.
  13. Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129:49.
  14. Burton JL, Harman RR, Peachey RD, Warin RP. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J 1978; 2:1190.
  15. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol 1977; 113:1043.
  16. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007; 143:1536.
  17. Wojnarowska F, Kirtschig G, Highet AS, et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147:214.
  18. Badalamenti SA, Kerdel FA. Azathioprine. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, Philadelphia 2007. p.182.
  19. Fox JC, Kenkare S, Petronic-Rosic V, et al. Bullous pemphigoid in late childhood successfully treated with mycophenolate mofetil as an adjuvant therapy. Pediatr Dermatol 2010; 27:537.
  20. Eskin-Schwartz M, David M, Mimouni D. Mycophenolate mofetil for the management of autoimmune bullous diseases. Dermatol Clin 2011; 29:555.
  21. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999; 40:957.
  22. Böhm M, Beissert S, Schwarz T, et al. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997; 349:541.
  23. Nousari HC, Griffin WA, Anhalt GJ. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol 1998; 39:497.
  24. Tursen U, Guney A, Kaya T, Ikizoglu G. Treatment of bullous pemphigoid with enteric-coated mycophenolate sodium. J Eur Acad Dermatol Venereol 2007; 21:542.
  25. Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatolog Treat 2006; 17:370.
  26. Sokumbi O, el-Azhary RA, Langman LJ. Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases. J Am Acad Dermatol 2013; 68:36.
  27. Kwatra SG, Jorizzo JL. Bullous pemphigoid: a case series with emphasis on long-term remission off therapy. J Dermatolog Treat 2013; 24:327.
  28. Du-Thanh A, Merlet S, Maillard H, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol 2011; 165:1337.
  29. Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol 2008; 144:612.
  30. Gunay U, Gunduz K, Ermertcan AT, Kandiloğlu AR. Coexistence of psoriasis and bullous pemphigoid: remission with low-dose methotrexate. Cutan Ocul Toxicol 2013; 32:168.
  31. Gürcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009; 161:723.
  32. Heilborn JD, Ståhle-Bäckdahl M, Albertioni F, et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999; 40:741.
  33. Bara C, Maillard H, Briand N, Celerier P. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol 2003; 139:1506.
  34. Kolbach DN, Remme JJ, Bos WH, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol 1995; 133:88.
  35. Goon AT, Tan SH, Khoo LS, Tan T. Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore. Singapore Med J 2000; 41:327.
  36. Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch Dermatol 1986; 122:670.
  37. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130:753.
  38. Thomas I, Khorenian S, Arbesfeld DM. Treatment of generalized bullous pemphigoid with oral tetracycline. J Am Acad Dermatol 1993; 28:74.
  39. Safa G, Darrieux L. Nonbullous pemphigoid treated with doxycycline monotherapy: report of 4 cases. J Am Acad Dermatol 2011; 64:e116.
  40. Kirtschig G, Khumalo NP. Management of bullous pemphigoid: recommendations for immunomodulatory treatments. Am J Clin Dermatol 2004; 5:319.
  41. Majmudar V, Herath D, O'Toole EA, Harrison A. Bullous pemphigoid of childhood: a rare disease with diagnostic and management challenges. Clin Exp Dermatol 2010; 35:213.
  42. Fox BJ, Odom RB, Findlay RF. Erythromycin therapy in bullous pemphigoid: possible anti-inflammatory effects. J Am Acad Dermatol 1982; 7:504.
  43. Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 2009; 10:383.
  44. Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996; 34:683.
  45. Czernik A, Toosi S, Bystryn JC, Grando SA. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity 2012; 45:111.
  46. Chee SN, Murrell DF. The use of intravenous immunoglobulin in autoimmune bullous diseases. Immunol Allergy Clin North Am 2012; 32:323.
  47. Czernik A, Bystryn JC. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. Arch Dermatol 2008; 144:658.
  48. Gaitanis G, Alexis I, Pelidou SH, et al. High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid. Eur J Dermatol 2012; 22:363.
  49. Sami N, Ali S, Bhol KC, Ahmed AR. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2003; 17:641.
  50. Lourari S, Herve C, Doffoel-Hantz V, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol 2011; 25:1238.
  51. Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011; 65:552.
  52. Calcaterra R, Carducci M, Franco G, et al. Topical tacrolimus treatment for localized pretibial bullous phemphigoid. J Eur Acad Dermatol Venereol 2009; 23:177.
  53. Ko MJ, Chu CY. Topical tacrolimus therapy for localized bullous pemphigoid. Br J Dermatol 2003; 149:1079.
  54. Curley RK, Holden CA. Steroid-resistant bullous pemphigoid treated with cyclosporin A. Clin Exp Dermatol 1991; 16:68.
  55. Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985; 1:334.
  56. Chave TA, Mortimer NJ, Shah DS, Hutchinson PE. Chlorambucil as a steroid-sparing agent in bullous pemphigoid. Br J Dermatol 2004; 151:1107.
  57. Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol 1990; 22:796.
  58. Guilabert A, Lozano F, Iranzo P, et al. A case of aggressive bullous pemphigoid associated with the defective functional variant of Fc gamma receptor IIb: implications for pathogenesis? J Am Acad Dermatol 2011; 65:1062.
  59. Dawe RS, Naidoo DK, Ferguson J. Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br J Dermatol 1997; 137:826.
  60. Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent. Arch Dermatol 2000; 136:1204.
  61. Dufour C, Souillet AL, Chaneliere C, et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol 2012; 166:1140.
  62. London VA, Kim GH, Fairley JA, Woodley DT. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol 2012; 148:1241.
  63. Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009; 123:704.
  64. Yu KK, Crew AB, Messingham KA, et al. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol 2014; 71:468.
  65. Ino N, Kamata N, Matsuura C, et al. Immunoadsorption for the treatment of bullous pemphigoid. Ther Apher 1997; 1:372.
  66. Müller PA, Bröcker EB, Klinker E, et al. Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption. Dermatology 2012; 224:224.
  67. Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet 1984; 2:486.
  68. Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 2011; 9:844.
  69. Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136:174.
  70. Fichel F, Barbe C, Joly P, et al. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study. JAMA Dermatol 2014; 150:25.
  71. Bernard P, Reguiai Z, Tancrède-Bohin E, et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009; 145:537.
  72. Risser J, Lewis K, Weinstock MA. Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol 2009; 145:1005.
  73. Parker SR, Dyson S, Brisman S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008; 59:582.
  74. Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998; 134:465.
  75. Cortés B, Marazza G, Naldi L, et al. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol 2011; 165:368.
  76. Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132:1998.
  77. Gual A, Mascaró JM Jr, Rojas-Farreras S, et al. Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre. J Eur Acad Dermatol Venereol 2014; 28:500.
  78. Cai SC, Allen JC, Lim YL, et al. Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre. Br J Dermatol 2014; 170:1319.
  79. Lee JH, Kim SC. Mortality of patients with bullous pemphigoid in Korea. J Am Acad Dermatol 2014; 71:676.
  80. Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 1992; 26:585.
  81. Bernard P, Enginger V, Venot J, et al. [Survival prognosis in pemphigoid. A cohort analysis of 78 patients]. Ann Dermatol Venereol 1995; 122:751.
  82. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002; 138:903.
  83. Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005; 141:691.
  84. Gudi VS, White MI, Cruickshank N, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol 2005; 153:424.
  85. Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ 2008; 337:a180.
  86. Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2004; 122:1091.